Allogeneic islet cells implant on poly-l-lactide matrix to reduce hyperglycaemia in streptozotocin-induced diabetic rat
Autor: | Ursula Weber, Ilhamjaya Patellongi, Makbul Aman, Hans U. Baer, Andreas L. Serra, Siufui Hendrawan, Irawan Yusuf, Barlian Sutedja, Gatot S. Lawrence, Mochammad Hatta |
---|---|
Rok vydání: | 2017 |
Předmět: |
Blood Glucose
Male 0301 basic medicine endocrine system medicine.medical_specialty Cell Survival Polyesters Endocrinology Diabetes and Metabolism medicine.medical_treatment Cell Culture Techniques Islets of Langerhans Transplantation Cell Separation Diabetes Mellitus Experimental Rats Sprague-Dawley Extracellular matrix Islets of Langerhans 03 medical and health sciences 0302 clinical medicine Islet cells Diabetes mellitus Internal medicine medicine Animals Insulin Islet cell transplantation geography geography.geographical_feature_category Hepatology business.industry Body Weight Gastroenterology medicine.disease Streptozotocin Islet Rats Surgery 030104 developmental biology Endocrinology Hyperglycemia 030211 gastroenterology & hepatology Implant business medicine.drug |
Zdroj: | Pancreatology. 17:411-418 |
ISSN: | 1424-3903 |
Popis: | Objective To demonstrate the effects of allogeneic islet cell matrix implants for glycaemic control in rats with induced diabetes. Method Sprague-Dawley rats were used as allogeneic donors of islet cells. Cells were seeded on three-dimensional proprietary poly-( l -lactide) matrices. Animals were rendered diabetic and a week later a matrix seeded with islet cells (IMI group) or a control matrix (placebo group) was implanted in the small bowel mesentery. Blood glucose levels were measured weekly for 12 weeks. After sacrifice, implant sections were Gomori stained for beta-cells and immuno-stained for insulin 3, 4, 5, and 6 months post implantation. Results 82% of seeded islet cells attached to the matrices. In the IMI group blood glucose levels were significantly reduced after implantation compared with before implantation across several time points. In the IMI group beta-cells and insulin-positive cells were identified at the implant site. Conclusion The islet cell matrix implant reduced the blood glucose levels although complete normo-glycaemia was not established. The islet cell matrix implant may serve as an additional option for islet cell transplantation using 3D scaffold platforms for better survival and function of the islet cells. |
Databáze: | OpenAIRE |
Externí odkaz: |